Mylan shareholders back proposed Perrigo purchase.» Read More
The "Halftime Report" traders give their trades for the second half.
*M&A speculation boosts Burberry, Mediaset. Burberry was flagged by Goldman Sachs among shares on its "conviction buy" lists for which its sees a bid probability of 30 percent or more. Italian media group Mediaset rose 2.2 percent after Mediobanca tipped it as a bid target for France's Vivendi.
*M&A speculation boosts Burberry, Mediaset. Burberry was flagged by Goldman Sachs among shares on its "conviction buy" lists for which its sees a bid probability of 30 percent or more. Italian media group Mediaset rose 2.8 percent after Mediobanca flagged it as a bid target for France's Vivendi.
*Mylan jumps after offering to buy Perrigo for about $29 bln. *Alcoa flat in extended trading after results. NEW YORK, April 8- U.S. stocks ended a volatile session with modest gains on Wednesday after minutes from a U.S.
*Fed minutes indicate rate hike in 2015, but members differ on month. *Mylan jumps after offering to buy Perrigo for about $29 bln. NEW YORK, April 8- U.S. stocks rose on Wednesday, but trading was volatile following the release of minutes from the U.S.
*Mylan jumps after offering to buy Perrigo for about $29 bln. Mylan shares jumped 14.4 percent to $68.15, boosting the Nasdaq and the S&P healthcare sector, on news it offered to buy Perrigo for about $29 billion in cash and stock. Perrigo shares jumped 21.7 percent to $200.50.
Perrigo is set to close a huge deal for Omega Pharmaceuticals. Perrigo CEO Joseph Papa, discusses the benefits of the deal, and the company's move to Ireland.
Some of the names on the move ahead of the open.
We're moving into a time of year that’s been difficult for bulls, historically. However, if the market does sell off, Cramer won't cry.
The stock market might be making new all-time highs on almost a daily basis, but that doesn’t mean there isn’t bargain to be had.
U.S. generic drug rules have been manipulated by brand-name drug companies to keep cheaper competition off the market, a report says.
U.S. health officials finalized guidelines for infant formula makers that aim to ensure products meet certain quality controls to keep them safe.
Some of Wednesday's midday movers:
There are some solid reasons why Pfizer's reported $101 billion bid for AstraZeneca makes some sense, analysts said.
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
A couple of stocks stand to gain over the next two weeks, Paul Hickey of Bespoke Investment Group says.
Events in Ukraine appear to be improving, but it may only be a matter of time before they take another turn for the worse. Are you prepared?
In his book "Get Rich Carefully," CNBC's "Mad Money" host explains how spotting long-term megatrends can help investors surf the wave of profitability.
Cramer believes there’s always opportunity in the market. You simply have to know where to look.
Perrigo CEO Joseph Papa discusses how its new headquarters in Ireland will impact its tax structure, and whether the company will add a dividend.